licensing

News

Merck bets on Inspirna’s colorectal cancer drug ompenaclid

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna

News

Astellas strikes $1.7bn SIRP drug deal with Elpiscience

Astellas has struck a deal with fellow Japanese pharma company Elpiscience to develop up to four cancer immunotherapies that work by revving up the activity of macrophages

News

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront

News

BMS bolts on SystImmune bispecific ADC in $8.4bn deal

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending.

News

Merck grabs late-stage oncology drug from China’s Abbisko

Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT), a rare disea

News